MARKET

IMMP

IMMP

Immutep
NASDAQ
2.620
0.000
0.00%
After Hours: 2.620 0 0.00% 16:10 02/06 EST
OPEN
2.650
PREV CLOSE
2.620
HIGH
2.675
LOW
2.560
VOLUME
156.48K
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
1.320
MARKET CAP
386.11M
P/E (TTM)
-9.4483
1D
5D
1M
3M
1Y
5Y
1D
Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy
Benzinga · 1d ago
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Barchart · 1d ago
Immutep erreicht 50 % Patientenzahl in Phase-III-Studie TACTI-004 zu Lungenkrebs
Reuters · 2d ago
Immutep Reaches 50% Enrollment Milestone in Global Phase III TACTI-004 Trial for First-Line NSCLC
Reuters · 2d ago
Weekly Report: what happened at IMMP last week (0126-0130)?
Weekly Report · 5d ago
Immutep Secures Dr. Reddy’s Licensing Deal and Reports Strong Q2 FY26 Clinical and Cash Progress
TipRanks · 01/30 11:33
Immutep reports Q2 cash receipts from customers A$4,000
TipRanks · 01/29 13:21
Weekly Report: what happened at IMMP last week (0119-0123)?
Weekly Report · 01/26 10:01
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.